Recently, I’ve been looking into discussions about CDMO concept stocks and found that this sector is indeed worth paying more attention to. Speaking of which, the term CDMO is still a bit unfamiliar to many people; it’s actually short for Contract Development and Manufacturing Organization, simply put, companies that do R&D and manufacturing outsourcing for pharmaceutical companies.

Thinking back to 2023, Taiwan’s Polyu surged more than double due to the hype around CDMO concept stocks, and at that time, market expectations for this sector were quite high. Why was that? Mainly because global demand for new drug development was increasing, and pharmaceutical companies were increasingly inclined to outsource R&D and manufacturing to specialized CDMO firms, which could reduce costs and accelerate time to market.

From data, the global CDMO market size is indeed continuously expanding. According to previous forecasts, the market could reach $124.3 billion by 2025, and by 2030, it might surge to $231 billion, with a quite impressive growth rate. The driving forces are clear: one is the increasing healthcare demand driven by aging populations, and the other is pharmaceutical companies’ ongoing pursuit of cost reduction.

International leading CDMO companies like Lonza, WuXi AppTec, and Catalent have already established a solid position in this field. Lonza, as the world’s largest CDMO, had revenues exceeding $6.5 billion in 2022, with more than half of its income coming from its top ten clients. This stable customer base is a core advantage of the CDMO industry. WuXi’s figures are also strong, with combined revenues over $5.6 billion in 2022, and its growth rate is still accelerating.

Taiwan’s CDMO concept stocks are also rising. Companies like Polyu, Yongxin, and Handa are all entering this space. Although their scale is still smaller than international giants, their growth potential is even greater because of the smaller base and larger market space. Moreover, Taiwan has ample experience and talent reserves in outsourcing, and the government is actively promoting CDMO as a strategic industry for the future.

However, it’s important to note that as more companies enter this sector, competition will become fiercer. Those that can survive and continue to grow in the future are likely to be the leading firms with scale advantages and technological barriers. So, if you’re considering investing in CDMO concept stocks, choosing the top players might be a safer strategy.

Investment methods are also quite flexible: you can buy stocks directly, invest in related ETFs, or use CFDs for short-term trading. Each approach has its own pros and cons, depending on your investment style and risk tolerance.

Overall, the logic behind CDMO concept stocks remains valid; the long-term growth trend of the pharmaceutical market hasn’t changed. As a key part of the industry chain, CDMO still holds opportunities in the future. But short-term fluctuations are inevitable, so selecting good targets and managing risks are the keys to success.